Thyroid Diseases: Clinical Trials

145 trials for Thyroid Diseases, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

145 completed. 145 Phase 2, 22 Phase 1, 12 Phase 3.

By phase and status

PhaseTrialsStatus
Phase 2145Completed 145
Phase 122Completed 22
Phase 312Completed 12

Follow Thyroid Diseases: new trials by email Literature Review of Thyroid Diseases trials Research Report on Thyroid Diseases

Trials (filtered) newest first · largest first

All 145 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Effects of Different Administration Routes of Dexmedetomidine on Postoperative Sleep Quality in Patients Undergoing Thyroidectomy
Dexmedetomidine (DEX), Saline - Thyroid Diseases
Phase 1 / Phase 2CompletedThe Second People's Hospital of Huai'an1202026-01-052026-09-11
Oral Mecobalamin for TKI-Associated Hand-Foot Syndrome in Advanced Thyroid Cancer
Mecobalamin, Urea Ointment - Thyroid Cancer, Hand-foot Syndrome
Phase 2CompletedLi Zhihui1002025-04-122026-11-03
Identification of Nerves Using Fluorescein Sodium
Fluorescein Sodium - Pleomorphic Adenoma of the Parotid, Warthin Tumor
Phase 2CompletedStanford University82024-11-072026-05-20
A Study of IBI311 in Subjects With Inactive or Active Thyroid Eye Disease
IBI311 (20 mg), IBI311 (3-20 mg), IBI311 (10 mg) - Thyroid Eye Disease
Phase 2CompletedInnovent Biologics (Suzhou) Co. Ltd.382024-09-042025-10-03
Safety, Pharmacokinetics and Efficacy of MBX 2109 in Patients With Hypoparathyroidism
MBX 2109, Placebo - Hypoparathyroidism
Phase 2CompletedMBX Biosciences642024-08-082026-03-20
A Study to Evaluate the Efficacy and Safety of LASN01 in Patients With Thyroid Eye Disease
LASN01, Placebo - Thyroid Eye Disease, Graves Ophthalmopathy
Phase 2CompletedLassen Therapeutics Inc.412024-03-052026-03-09
A Study of SNS-101 (Anti VISTA) Monotherapy and in Combination With Cemiplimab in Patients With Advanced Solid Tumors
SNS-101 (anti-VISTA), Cemiplimab - Solid Tumor, Adult, Advanced Solid Tumor
Phase 1 / Phase 2CompletedSensei Biotherapeutics, Inc.982023-05-312026-09-02
Cabozantinib In Advanced Radioactive-Iodine Refractory Differentiated Thyroid Cancer.
Cabozantinib - Differentiated Thyroid Cancer
Phase 2CompletedGrupo Espanol de Tumores Neuroendocrinos412023-05-252026-05-04
A Proof-of-Concept Study to Assess Batoclimab in Participants With Graves' Disease
IMVT-1401 (batoclimab) - Graves Disease
Phase 2CompletedImmunovant Sciences GmbH322023-05-152026-08-13
Study of XP-8121 For the Treatment of Adult Subjects With Hypothyroidism
levothyroxine sodium - Hypothyroidism
Phase 2CompletedXeris Pharmaceuticals462023-05-152025-07-03
A Clinical Trial of KVA12123 [TBS-2025] Treatment Alone and in Combination With Pembrolizumab In Advanced Solid Tumors (VISTA-101)
KVA12123 - Dose Escalation, KVA12123 Plus Pembrolizumab - Dose Escalation, KVA12123 - Dose Expansion - Cancer, Solid Tumor
Phase 1 / Phase 2CompletedKineta Inc.402023-03-032026-10-05
A Study Evaluation the Safety and Efficacy of Hormone Replacement Therapy With North Star Compared to Levothyroxine in Patients With Primary Hypothyroidism
North Star, Levothyroxine - Hypothyroidism
Phase 2CompletedNeuvosyn Laboratories, LLC3032023-02-282026-02-18
Efficacy and Safety of Lonigutamab in Subjects With Thyroid Eye Disease (TED)
lonigutamab, Placebo - Thyroid Eye Disease
Phase 1 / Phase 2CompletedACELYRIN Inc.312023-02-142025-07-01
A Study of IBI311 in Subjects With Active Thyroid Eye Disease
IBI311, placebo - Thyroid Eye Disease
Phase 2 / Phase 3CompletedInnovent Biologics (Suzhou) Co. Ltd.1152023-02-142024-02-08
A Phase 2b, Study of Linsitinib in Subjects With Active, Moderate to Severe Thyroid Eye Disease (TED)
Linsitinib, Placebo - Thyroid Eye Disease, Graves Orbitopathy
Phase 2 / Phase 3CompletedSling Therapeutics, Inc.902022-07-012026-09-23
A Study to Evaluate the Safety, Preliminary Efficacy, and Pharmacokinetic Properties of LASN01 in Healthy Subjects and in Patients With Pulmonary Fibrosis or Thyroid Eye Disease
LASN01, Placebo - Pulmonary Fibrosis, Thyroid Eye Disease
Phase 1 / Phase 2CompletedLassen Therapeutics 1 PTY LTD752022-06-062024-12-30
Thyroid Hormone Supplementation in Patients With Septic Shock
triiodothyronine - Euthyroid Sick Syndromes, Septic Shock
Phase 2CompletedCantonal Hospital Zenica1082022-05-012023-09-28
A Study Evaluating the Safety and Efficacy of Hormone Replacement Therapy With ST-1891 Compared to Levothyroxine in Patients With Primary Hypothyroidism
ST-1891, Levothyroxine - Hypothyroidism
Phase 2CompletedSention Therapeutics, LLC4902022-04-292024-08-26
To Evaluate Efficacy and Safety of TT-00420 (Tinengotinib) as Monotherapy and Combination Therapy in Patients With Advanced Solid Tumors
TT-00420, Combination Product: Atezolizumab, Combination Product: Nab-Paclitaxel - Advanced Solid Tumor, Cholangiocarcinoma
Phase 1 / Phase 2CompletedTransThera Sciences (Nanjing), Inc.842022-04-132025-06-12
Use of 18F-PSMA-11 PET for Detection of Lesions in Iodine Refractory Thyroid Cancers
PET/CT scan F18-PSMA-11 - Thyroid Cancer
Phase 2CompletedUniversity Hospital, Ghent82022-01-242025-03-04

Showing 20 of 145. Sign in to see all of them.

Narrower conditions

Thyroid Neoplasms (88)  ·  Thyroid Cancer, Papillary (27)  ·  Adenocarcinoma, Follicular (22)  ·  Carcinoma, Medullary (17)  ·  Head and Neck Neoplasms (17)  ·  Graves Ophthalmopathy (15)  ·  Hypothyroidism (13)  ·  Thyroid Carcinoma, Anaplastic (11)  ·  Carcinoma, Non-Small-Cell Lung (10)  ·  Graves Disease (10)  ·  Neoplasms (9)  ·  Lung Neoplasms (8)  ·  Melanoma (8)  ·  Ovarian Neoplasms (7)

Broader conditions

Endocrine System Diseases (140)  ·  Neoplasms by Site (97)  ·  Endocrine Gland Neoplasms (94)  ·  Neoplasms (93)  ·  Head and Neck Neoplasms (80)  ·  Neoplasms by Histologic Type (51)  ·  Neoplasms, Glandular and Epithelial (44)  ·  Carcinoma (42)  ·  Adenocarcinoma (36)  ·  Adenocarcinoma, Papillary (26)  ·  Immune System Diseases (25)  ·  Neoplasms, Nerve Tissue (25)  ·  Neuroectodermal Tumors (25)  ·  Neoplasms, Germ Cell and Embryonal (24)

Interventions

Thyroxine (11)  ·  Triiodothyronine (11)  ·  Sorafenib (7)  ·  Magnetic Resonance Spectroscopy (5)  ·  Thyrotropin Alfa (5)  ·  Sunitinib (4)  ·  lenvatinib (4)  ·  2-phenyl-6-(2'-(4'-(ethoxycarbonyl)thiazolyl))thiazolo(3,2-b)(1,2,4)triazole (3)  ·  Cisplatin (3)  ·  Everolimus (3)  ·  Fluorodeoxyglucose F18 (3)  ·  Rituximab (3)  ·  pembrolizumab (3)  ·  vandetanib (3)  ·  4-amino-5-fluoro-3-(5-(4-methylpiperazin-1-yl)-1H-benzimidazol-2-yl)quinolin-2(1H)-one (2)

Sponsors

National Cancer Institute (NCI) (15)  ·  Dana-Farber Cancer Institute (4)  ·  National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) (4)  ·  Amgen (3)  ·  Eisai Inc. (3)  ·  Genzyme, a Sanofi Company (3)  ·  University of Pennsylvania (3)  ·  Academic and Community Cancer Research United (2)  ·  Bayer (2)  ·  Immunovant Sciences GmbH (2)  ·  Innovent Biologics (Suzhou) Co. Ltd. (2)  ·  Kenneth Ain (2)  ·  Memorial Sloan Kettering Cancer Center (2)  ·  Nantes University Hospital (2)  ·  Novartis Pharmaceuticals (2)

Countries

United States (87)  ·  France (20)  ·  Italy (15)  ·  Spain (14)  ·  Canada (13)  ·  China (13)  ·  United Kingdom (11)  ·  Belgium (10)  ·  South Korea (10)  ·  Germany (9)  ·  Australia (8)  ·  Denmark (8)  ·  Netherlands (6)  ·  Poland (5)  ·  Egypt (4)

Top investigators

Anne R Cappola, MD,ScM (2)  ·  David Pfister (2)  ·  Kartik Seghal, MD (2)  ·  Manisha Shah (2)  ·  Steven Sherman (2)  ·  AeRang Kim, MD (1)  ·  Ahmed Abdelal, MD (1)  ·  Ahmed M Sayed, Prof. (1)  ·  Alain Ravaud, Pr. (1)  ·  Alan L Ho (1)

Results publications

PMID 27240885, PMID 37934000, PMID 10427152, PMID 12050214, PMID 16384850, PMID 16522694, PMID 16864757, PMID 17985985, PMID 18596272, PMID 18854394, PMID 19158200, PMID 19265494, PMID 19773371, PMID 20189981, PMID 20447070, PMID 20484486, PMID 20519346, PMID 20632263, PMID 20739336, PMID 20739388, PMID 20837917, PMID 20851682, PMID 21865366, PMID 22743249, PMID 22753906, PMID 22898678, PMID 22983830, PMID 23009127, PMID 23204220, PMID 23585666, PMID 23726971, PMID 23990665, PMID 24050953, PMID 24178792, PMID 24374976, PMID 24651704, PMID 24844950, PMID 25101534, PMID 25315258, PMID 25343233, PMID 25581596, PMID 26088605, PMID 26195199, PMID 26221138, PMID 26671977, PMID 27392538, PMID 27797318, PMID 27974047, PMID 28299283, PMID 28301826

NIH funding

N01CM62207 (4), P30CA015083 (4), 2014 (3), 2016 (3), N01CM00099 (3), N01CM62201 (3), N01CM62206 (3), 2015 (2), N01CM00071 (2), N01CM62202 (2), N01CM62203 (2), N01CM62205 (2), P30CA014599 (2), P30CA016058 (2), R61HL146390 (2)